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Abstract
Background: The 17-alpha-alkylated derivatives of testosterone are often used for the prevention of oedematous
episodes in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE). However, these agents can have
many adverse effects, including erythrocytosis and polyglobulia. Our aim was to investigate occurrence of
erythrocytosis and polyglobulia after long-term danazol prophylaxis in C1-INH-HAE.
Methods: During the initial stage of our retrospective study, we explored whether C1-INH-HAE is associated
with susceptibility to erythrocytosis and/or polyglobulia. In the second stage, we analyzed the haematological
parameters of 39 C1-INH-HAE patients before, as well as after treatment with danazol for 1, 3, or 5 years. In the
third stage, we studied the incidence of erythrocytosis and of polyglobulia after dosing with danazol for more
than 5 years.
Results: We did not find any significant difference between C1-INH-HAE patients not receiving danazol and
healthy controls as regards the occurrence of erythrocytosis or polyglobulia. The haematological parameters
did not change after treatment with danazol for 1, 3, or 5 years. Platelet count was an exception-it decreased
significantly (p = 0.0115) versus baseline, but within the reference range. Treatment-related polyglobulia did
not occur. We observed erythrocytosis in a single female patient after 1-year-and in three female patients after
more than 5-year long-treatment with danazol. Erythrocytosis did not require intervention or the discontinuation of
danazol therapy.
Conclusions: We conclude that neither erythrocytosis, nor polyglobulia occurs more often in C1-INH-HAE patients than
in healthy individuals; it can be observed only sporadically even after treatment with danazol.
Keywords: Hereditary angioedema, C1-inhibitor deficiency, danazol, Prophylaxis, Haematology, Erythrocytosis,
Polyglobulia
Background
Hereditary angioedema resulting from the deficiency of the
C1-inhibitor (C1-INH-HAE) is a rare autosomal dominant
disorder. Its characteristic feature is bradykinin-mediated
angioedema, manifested by sudden episodes of subcuta-
neous and/or submucosal edema-formation. The manage-
ment of the disease consists of acute treatment, as well
as of the prevention of oedematous episodes. Currently,
antifibrinolytic agents, attenuated androgens (AAs),
plasma-derived C1-INH concentrate, and progestins
are available for prophylaxis [1]. In C1-INH-HAE, the
earliest and the most extensive experience is available
with attenuated androgens (e.g., methyltestosterone,
danazol, stanozolol, oxandrolone); however, the precise
mode of the action of these drugs is unknown. AAs are
thought to increase serum C1-INH level by stimulating
hepatic synthesis, and the expression of C1-INH mRNA
in peripheral blood mononuclear cells [2, 3]. Treatment
with these agents reduces the frequency and severity of
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attacks in 94–100 % of patients; however, 5–8 % do
not respond to danazol [4–6]. Even today, attenuated
androgens are commonly used for the prophylactic
treatment of C1-INH-HAE. However, these effective and
inexpensive agents for oral use can cause a variety of
adverse events [7].
The well-known side effects of AAs include the al-
teration of the plasma lipid profile [8], hepatotoxicity
[5], virilisation [9], psychiatric and behavioural effects
[10–12], the premature closure of epiphyses [13, 14],
impaired glucose tolerance and insulin resistance [15, 16],
as well as hypogonadism [17].
Moreover, AAs can influence haematological parame-
ters: their stimulatory effect on erythropoiesis may result
in erythrocytosis, and in the elevation of haemoglobin
level [7]. Erythrocytosis and polyglobulia increase blood
viscosity. As a result, the slowing of the circulation may
cause dizziness, headache, visual disturbances, mental
decline, as well as enhanced propensity to thrombo-
embolism in the blood vessels of the brain, limbs, and the
heart. Published experience with the haematological
adverse effects of AAs has been accumulated during
the danazol treatment of patients with endometriosis
[18], benign breast disease [19], Fanconi anaemia [20],
and idiopathic thrombocytopenic purpura (ITP) [21].
However, the findings from these studies are not fully
applicable to C1-INH-HAE patients, because this dis-
order requires longer drug therapy (lasting for years,
vs. 2–6 months in endometriosis), although with smaller
doses (33–200 mg vs. 400–600 mg in endometriosis, or
50–800 mg in ITP) [21]. In the literature, erythrocytosis
and polyglobulia are mentioned in two publications [4, 5],
whereas polyglobulia is identified in another paper [22],
as a possible adverse effect of AAs; however, long-term
follow-up studies have not yet been conducted in this
subject.
In view of the foregoing, we intended to explore-by
implementing a follow-up study-the effects of long-term
danazol therapy on the haematological parameters of
C1-INH-HAE patients. We also investigated whether





We conducted our prospective study in the National
Angioedema Centre (Budapest, Hungary). We investigated
the incidence of erythrocytosis and polyglobulia among
145 C1-INH-HAE patients, diagnosed and followed up at
the Centre in compliance with the international criteria
[23]. The periodic follow-up evaluation performed on
these patients at least once a year includes, among others,
a haematology screen. The laboratory findings are
recorded in the National HAE Register; we analyzed
the data accumulated between 1993 and 2015.
Controls
In the age- and gender-matched group of healthy controls,
the haematological parameters for analysis were obtained
from a blood sample drawn for the purposes of a health
status screening. The demographic properties of these
subjects are detailed in the Results section.
All patients gave informed consent; and the study was
endorsed by the Ethical Committee of the Semmelweis
University (Budapest), and it was implemented in con-
formity with the declaration of Helsinki.
Complete blood count
The haematological parameters – white blood cell count
(WBC), red blood cell count (RBC), haemoglobin level
(Hb), haematocrit (Hct), and platelet count (PLT)-were
measured with a digital analyzer (Cobas Integra 400/800,
Roche, Basel, Switzerland). Erythrocytosis was defined as
a RBC count >5.9 × 1012/L in males and >5.1 × 1012/L
in females. The threshold values for polyglobulia were
Hct >0.52 L/L in males, and >0.48 L/L in females [24].
Study design
In the first stage of the study We compared the inci-
dence of erythrocytosis and of polyglobulia in C1-
INH-HAE patients who have never been treated with
danazol, and in healthy controls. We used the following
two methods for this purpose:
1. We took into account the initial laboratory findings
of C1-INH-HAE patients over the age of 18 years,
who had never before received danazol. Seventy-six
of the 145 C1-INH-HAE patients fulfilled these criteria.
By analyzing RBC and Hct values, we ascertained the
occurrences of erythrocytosis and of polyglobulia
among these patients and among the controls.
2. In the year 2012, there were 51 individuals among
the 145 C1-INH-HAE patients, who had never before
received danazol. We compared the haematological
parameters of these patients with those of the controls
to determine the number of cases with erythrocytosis
and polyglobulia in these two groups.
In the second stage of the study We examined the in-
fluence of long-term danazol treatment on the haemato-
logical parameters of the patients, as well as looked for
relationships among the latter and danazol dose. To this
end, we compared the haematological parameters mea-
sured before the start of danazol therapy with those ob-
tained after 1, 3, and 5 years of treatment in 39 out of
145 C1-INH-HAE patients. The haematological values
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were determined in the same laboratory, using the same
method. Two female patients were excluded from the
analysis, as they had erythrocytosis even before the start
of danazol treatment.
In the third stage of the study We surveyed the inci-
dence of erythrocytosis and polyglobulia in C1-INH-HAE
patients who had received danazol (50–200 mg/day) lon-
ger than 5 years. We determined the duration of danazol
treatment by reviewing the database of the National HAE
Registry, as well as the medical records of the patients-and
then, created groups according to the duration of treat-
ment (5–10 years, 10–15 years, 15–20 years, 20–25 years,
and 25– 30 years). We ascertained the incidence of
erythrocytosis and of polyglobulia by taking into account
the laboratory findings obtained for the first time after the
discontinuation of danazol.
Statistical analysis
We performed the statistical analyses with the Graph-
PadPrism software, version 6.00 (GraphPad Software, San
Diego, California, USA). The incidences of erythrocytosis
and of polyglobulia were compared using Fischer’s exact
test. Samples drawn before the start, as well as after 1, 3,
or 5 years of danazol treatment were evaluated with paired
t-test (Wilcoxon test), and ANOVA, by applying Spear-
man’s correlation during the analysis of danazol doses.
A p < 0.05 was considered statistically significant in all
analyses.
Results
The incidence of erythrocytosis and of polyglobulia in
C1-INH-HAE patients who have never received danazol,
compared with healthy controls
I/1. We did not find any difference (p > 0.05) between
C1-INH-HAE patients never treated with danazol
(n = 76; 31 males [mean age: 31.01 years, min.:
18.10 years, max.: 58.50 years]) and 45 females [mean
age: 33.21 years, min.: 18.10 years, max.: 73.21 years)])
and healthy controls (n = 141; 57 males [mean age:
31.00 years, min.: 21.00 years, max.: 37.00 years] and
84 females [mean age: 33.00 years, min.: 22.00 years,
max.: 52.00 years]), as regards the incidence of
erythrocytosis and of polyglobulia (Table 1).
I/2. Comparing the laboratory parameters obtained in
the year 2012 from C1-INH-HAE patients who had
never before received danazol (n = 51; 21 males
[mean age: 37.39 years, min.: 18.10 years, max.:
63.27 years], and 30 females [mean age: 38.64 years,
min.: 22.50 years, max.: 82.02 years)]) with those of
age- and gender-matched healthy controls (n = 210;
89 males [mean age: 38.00 years, min.: 23.00 years,
max.: 67.00 years] and 121 females [mean age:
38.00 years, min.: 21.00 years, max.: 59.00 years]) did
not reveal any difference either in the incidence of
erythrocytosis and/or polyglobulia-see Table 2.
The effect of long-term treatment with danazol on
haematological parameters
We compared the haematological parameters measured
before the start of danazol therapy with those obtained
after 1, 3, and 5 years of treatment-in 39 out of 145 C1-
INH-HAE patients (37 with HAE type I and 2 with HAE
type II) – see Fig. 1. During the 5-year long follow-up,
data were available from a smaller number of patients
during years 3 to 5 than in the initial year. The demo-
graphic data of the patients are detailed as follows.
Patients receiving one-year danazol prophylaxis
Thirty-nine patients received danazol prophylaxis for a
year. This group included 18 males (mean age: 37.23 years,
min.: 18.00 years, max.: 66.46 years) and 21 females (mean
age: 36.72 years, min.: 18.26 years, max.: 65.57 years).
Table 1 The incidence of erythrocytosis and polyglobulia in




danazol (n = 76)
Healthy controls
(n = 141)
Erythrocytosis Males 0 1
Females 1 2
No erythrocytosis Males 31 56
Females 44 82
Polyglobulia Males 0 0
Females 0 0
No polyglobulia Males 31 57
Females 45 84
Table 2 The incidence of erythrocytosis and polyglobulia
(based on haematology parameters measured in 2012) in
C1-INH-HAE patients who have never been treated with danazol,
vs. in healthy controls
C1-INH-HAE patients
never treated with
danazol (n = 51)
Healthy controls
(n = 210)
Erythrocytosis Males 0 2
Females 1 6
No erythrocytosis Males 21 87
Females 29 115
Polyglobulia Males 0 0
Females 0 1
No polyglobulia Males 21 89
Females 30 120
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Fig. 1 (See legend on next page.)
Kőhalmi et al. Orphanet Journal of Rare Diseases  (2016) 11:18 Page 4 of 7
Patients receiving three-year danazol prophylaxis
Thirty-three patients were enrolled into this group,
which comprised 16 males (mean age: 35.64 years, min.:
18.00 years, max.: 45.46 years) and 17 females (mean
age: 33.81 years, min.: 18.27 years, max.: 47.29 years).
Patients receiving five-year danazol prophylaxis
Danazol prophylaxis was administered over 5 years to 30
patients-that is, to 15 males (mean age: 35.17 years, min.:
18.00 years, max.: 45.46 years) and 15 females (mean age:
34.32 years, min.: 18.27 years, max.: 47.29 years).
Compared with baseline, we could not detect any
significant changes in the haematological parameters
of the male patients treated with danazol for 1, 3, or
5 years. As regards the female patients, the same applies
to RBC, Hb, and Hct. However, WBC and PLT values were
significantly (p = 0.0067, and p = 0.0203) lower after 5 years
of danazol treatment than at baseline (Table 3). We
observed RBC and Hct values beyond the upper limit
of the normal range in a single patient. In this female
subject (Patient #1), erythrocytosis occurred after one-
year treatment with danazol, and persisted throughout
the follow-up period (i.e., beyond years 3 and 5). This
patient started taking danazol at the age of 44 years.
As her last menses occurred at the age of 46 years,
erythrocytosis cannot be interpreted as a menopausal
change. The patient has never smoked in her life. The
specialist consultation done in 2012 excluded the
presence of any unrecognised haematological disorder
(the patient was negative for the JAK-2 mutation), and
recommended watchful waiting. Danazol treatment
was not stopped. In consideration of the foregoing,
this case of erythrocytosis could be attributed to dana-
zol treatment.
Elevated Hct was detected in the same female patient
who developed erythrocytosis as well. This patient had
polyglobulia after treatment with danazol for 1 and 3 years.
However, polyglobulia was no longer detectable after
5 years, and hence its relation to danazol was improbable.
In males, RBC and/or Hct values beyond the reference
range were not observed-neither before, nor after treat-
ment with danazol for 1, 3, or 5 years.
We also studied whether the dose of danazol influ-
ences haematological parameters (WBC, RBC, Hb, Hct,
and PLT). We subtracted the laboratory values obtained
in year 5 from baseline values, and compared the results
with the daily dose of danazol. After 5 years of prophy-
laxis, the mean daily dose of danazol was 106.5 (50–200)
mg in males, and 108 (50–220) mg in females.
The Spearman’s correlation test did not reveal-either
in males, or in females-any significant relationship be-
tween danazol dose and the values of haematological in-
dices after 5 years of danazol treatment.
III. Fifty patients altogether (25 males and 25 females)
received danazol for more than 5 years. The duration of
treatment was 5–10 years in 12 patients (6 females and
6 males); >10–15 years in 21 patients (10 males and 11
females); >15–20 years in 10 patients (5 males and 5
Table 3 The median values of the haematological parameters of the 39 C1-INH-HAE patients taking danazol before treatment as
well as after 1-, 3-, and 5-year treatment with danazol












WBC Males 4.0–10.0 × 109/L 8.54 (5.83–10.5) 6.76 (5.70–9.06) 7.90 (5.83–10.0) 6.57 (5.40–8.63) 8.30 (5.83–10.10) 7.83 (5.52–8.53)
Females 7.60 (6.70–10.57) 7.80 (6.55–9.22) 7.60 (7.03–9.88) 7.88 (6.48–8.61) 7.60 (6.80–10.7) 6.45 (5.43–7.12)*
RBC Males 4.50–5.90 × 1012/L 5.17 (4.82–5.37) 5.14 (4.79–5.35) 5.21 (4.84–5.38) 5.14 (4.70–5.29) 5.20 (4.82–5.39) 5.21 (4.74–5.52)
Females 4.10–5.10 × 1012/L 4.60 (4.33–4.73) 4.61 (4.31–4.81) 4.60 (4.33–4.73) 4.55 (4.45–4.69) 4.62 (4.27–4.76) 4.60 (4.32–4.67)
Hb Males 140–175 g/L 154 (149–161) 153 (146–160) 154 (152–161) 154 (144–158) 156 (151–161) 157 (151–162)
Females 123–153 g/L 133 (124–142) 137 (127–140) 133 (122–141) 135 (131–139) 133 (124–142) 138 (129–144)
Hct Males 0.36–0.48 L/L 0.46 (0.43–0.48) 0.45 (0.42–0.46) 0.46 (0.43–0.48) 0.45 (0.43–0.46) 0.45 (0.43–0.48) 0.45 (0.44–0.48)
Females 0.35–0.45 L/L 0.39 (0.38–0.42) 0.42 (0.38–0.42) 0.39 (0.38–0.42) 0.40 (0.39–0.41) 0.39 (0.38–0.42) 0.41 (0.38–0.43)
PLT Males 150–400 × 109/L 270 (232–300) 254 (230–315) 270 (231–314) 258 (227–333) 263 (230–322) 241 (222–285)
Females 291 (246–329) 265 (248–323) 302 (250–346) 286 (253–313) 302 (257–336) 262 (218–297)*
The median values of the haematological parameters of the 39 C1-INH-HAE patients (18 males and 21 females) taking danazol (with 25th and 75th percentiles in
parentheses) before treatment as well as 1-, 3-, and 5-year treatment with danazol, as analyzed by a paired (Wilcoxon’s) t-test. A significance of p < 0.05 is indicated
by an asterisk (*)
(See figure on previous page.)
Fig. 1 RBC, Hb, Hct, WBC, and PLT values of the 39 C1-INH-HAE patients treated with danazol at baseline and after 1, 3, and 5 years of dosing.
RBC, Hb, Hct, WBC, and PLT values of the 39 C1-INH-HAE patients (18 males and 21 females) treated with danazol at baseline and after 1, 3, and
5 years of dosing (ANOVA test). Males are identified by black squares, whereas females are identified by black dots. Where different for males and
females, the reference range is depicted by a continuous line for the former, and by a dotted line for the latter
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females); >20–25 years in 6 patients (3 males, 3 females);
and >25– 30 years in a single male patient. None of the
male patients developed erythrocytosis or polyglobulia,
whereas erythrocytosis occurred in three female patients;
we did not observe polyglobulia even after treatment
with danazol for 5 years. Of these three female patients,
we described the case of Patient #1 in the foregoing. In
this instance, erythrocytosis persisted 16 years after the
start of danazol treatment (with a mean daily dose of
116.7 [50–200] mg). As regards the other two female
patients with erythrocytosis, we monitored Patient #2
for 9 years, but did not detect any increase of RBC
count-except the year 2015. It must be noted, however,
that at the time of blood sampling, there were 25–30
WBCs, 2–3 RBCs with many epithelial cells and bacteria
in the urinary sediment, as well as the urine culture was
positive for Streptococcus agalactiae. This patient took da-
nazol in an average daily dose of 58.3 (50–100) mg. We
have been monitoring the laboratory parameters of Patient
#3 for 20 years. During this period, we found RBC values
above 5.1 × 1012/L only during the last 2 years. Neverthe-
less, this patient had additional predisposing factors for
erythrocytosis (i.e., smoking and hypertension). This
patient received danazol in a mean daily dose of 147.1 mg
(100–300 mg) for 20 years.
Discussion
These findings appear remarkable, as our study was the
first to demonstrate the lack of any difference between
C1-INH-HAE patients and healthy individuals as regards
the incidence of erythrocytosis and of polyglobulia. An-
other important aspect of this study is that it analyzed
these reactions-possible adverse effects of long-term
danazol treatment-during the systematic and long-term
follow-up of a larger patient population, by taking into
account their medical history, age and gender, as well as
the dose and duration of danazol treatment. Although
both erythrocytosis and polyglobulia have been reported
in C1-INH-HAE patients as adverse events associated
with long-term danazol prophylaxis, we did not observe
any significant increase of RBC and Hct values even after
5 years of treatment [4, 5, 22]. In particular, the RBC and
Hct values of these patients remained within the reference
range – with the exception of three female patients. How-
ever, the causal role of danazol in inducing erythrocytosis
may be considered in only one of these three patients.
The dose of danazol did not influence haematological
parameters. This is an apparent benefit from our effort to
administer the lowest effective dose, which did not exceed
220 mg. Bork et al. reported similar observations: RBC in-
creased in only two out of their 118 C1-INH-HAE pa-
tients on danazol treatment, which was not discontinued,
notwithstanding the laboratory abnormalities [5]. Cicardi
et al. studied 61 C1-INH-HAE patients receiving long-
term danazol therapy, and found mild polyglobulia in just
one male, and in one female subject [4]. However, these
studies did not specify the dose and the duration of da-
nazol treatment, or the details of the patient follow-up
performed to detect erythrocytosis. Zurlo & Frank [22]
published somewhat different results: they observed
polyglobulia in 18 out of their 82 C1-INH-HAE patients
on long-term danazol prophylaxis. It is important to note
that at the outset, these patients received danazol in a
much larger, 600 mg/day dose, which was tapered to the
lowest effective level only later. The highest observed Hb
and Hct values were 182 g/L, and 0.52, respectively. Zurlo
& Frank diagnosed thrombocytosis in 15 C1-INH-HAE
patients, but none of their subjects with polyglobulia or
thrombocytosis suffered thrombotic events [22]. Danazol
has been observed to stimulate thrombopoiesis-this is why
it is used for the treatment of ITP [21]. Considering this
along with our findings, we consider the significant reduc-
tion of platelet count in female C1-INH-HAE patients
after 5 years of danazol treatment particularly intriguing
and remarkable.
Conclusion
In summary of our results, we can conclude that treat-
ment with the lowest effective (33–220 mg/day) doses of
danazol-an agent used for the treatment of C1-INH-
HAE in clinical practice for nearly four decades-did not
induce haematological abnormalities that would require
the discontinuation of dosing, even after long-term use.
Because of the sporadic occurrence of erythrocytosis
observed in our study, patients on long-term danazol ther-
apy should undergo follow-up evaluation once a year at the
least. On these occasions, it is recommended to check
haematological parameters in addition to the appraisal of
hepatic and renal function, as well as of the serum lipid
profile, and to performing abdominal ultrasound imaging.
This practice affords early recognition of the adverse effects
of danazol-and hence, it makes it possible to prevent con-
secutive disorders and to adjust the therapy as necessary.
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